Novosibirsk State University and the E.N. Meshalkin National Medical Research Center conducted the first CT scan in Siberia on mini-pigs.

Translation. Region: Russian Federation –

Source: Novosibirsk State University –

An important disclaimer is at the bottom of this article.

In the Laboratory of Nuclear and Innovative Medicine Faculty of Physics of Novosibirsk State University A CT scan of minipigs was conducted for the first time. This study was conducted last week as part of a scientific collaboration between the Novosibirsk State University Laboratory of Animal Health, Physics, and scientists from the E.N. Meshalkin National Medical Research Center of the Russian Ministry of Health. Two Minisibs pigs, bred at the Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, were used as animal models. Each animal weighed 80 kg and was two years old. The study lasted approximately one hour per animal. Only one area of the body—the chest—was scanned, as the scientists needed to obtain high-quality 3D images of heart and lung sections. The minipigs were anesthetized during the procedures. The study will continue next year.

— Today, specialists from the National Medical Research Center named after Academician E.N. Meshalkina, together with NSU scientists, is conducting multislice computed tomography of the heart with contrast as part of their scientific activities. Our goal is to identify the features of the anatomical structure of the heart in two individuals of mini-pigs. The results of computed tomography will complement our electrophysiological study of the heart, which will allow us to obtain a complete electro-anatomical picture of the heart of these animals, on the basis of which in the future we will be able to conduct research aimed at the use of cellular technologies. The goal of today’s collaborative research is to determine the exact anatomical structure of each animal’s heart. Previously, we could only obtain information about the electrophysiological structure of the heart of animals, which did not provide an idea of ​​the topographic distribution of its sections in each individual animal. However, in our experience, even in individuals from the same drainage, the structure and size of the heart and its chambers are different. Thanks to the technical capabilities of LNAIM NSU, we can take advantage of the unique opportunity to conduct a multispiral computed tomographic study, and then, on the basis of our own experimental biological clinic, do electrophysiological mapping of the heart and obtain a comprehensive electroanatomical map for each animal. Thus, for each animal model studied, we will have a topographical and electroanatomical picture of the heart. In the next step, we will combine them to determine exactly where the pacemakers of the heart are located in relation to the precise topographic anatomy of each animal. Such studies can be carried out in large scientific centers – for example, at Moscow State University. M.V. Lomonosov or at Sechenov University. This is the first time such a study has been carried out beyond the Urals, said a leading researcher at the Laboratory of Experimental Surgery and Morphology of the Institute of Experimental Biology and Medicine of the Federal State Budgetary Institution “National Medical Research Center named after. Academician E.N. Meshalkin” of the Ministry of Health of Russia David Sergeevichev.

The cardiac pacemaker is a section of the heart muscle (the sinoatrial and atrioventricular nodes) that generates electrical impulses, setting the heart rate and rhythm. It is a natural "generator" that ensures the coordinated functioning of all parts of the heart.

The research is being conducted to develop a biologically derived cardiac pacemaker. Researchers at the E.N. Meshalkin National Medical Research Center of the Russian Ministry of Health are conducting this research under an interdisciplinary grant from the Russian Science Foundation. Comprehensive research is required to obtain additional information on the electroanatomical topographic structure of the heart, so that during experiments, scientists can accurately position the pacemaker in areas of the heart where its activity can be recorded.

"Mini-sibs are an ideal animal model for two reasons. First, their weight and height are very similar to humans. As adults, they reach an average weight of 70 kg, with some individuals reaching 100-130 kg, but never exceeding this weight. Second, the anatomical structure of these animals' hearts is quite similar to that of humans, and their electrical structure is almost identical to that of humans. Therefore, in terms of the applicability of experimental research results, they are an excellent model for translating animal experiments into human clinical practice," explained David Sergeevich.

This isn't the first time NSU LYAIM PhD specialists have performed CT scans on such large animals. As part of a project for preclinical trials of neutron capture therapy for cancer, they conducted similar studies on large-breed dogs, including some weighing approximately 60 kg. However, the anatomical structure of mini-pigs differs significantly from that of dogs, so the scientists had to practice positioning the animals on the CT table.

"The CT scan went quite quickly, as we were working with only one area—the chest—and specifically scanning the heart and blood vessels. Due to the animals' large body sizes, we had to adjust the settings and create new protocols, but this didn't present any difficulties. All scanning phases were followed. We didn't encounter any anticipated complications, except for one—the animals' heavy weight. It was quite challenging to lift them onto the scanner table and secure them in the correct position. We had to first lay a blanket over the table and securely fasten the animals with straps to achieve perfect balance and symmetry. However, we gained experience working with this type of animal model, which will be useful in the future. We've previously developed skills working with a variety of animals—we've scanned not only cats, dogs, rabbits, and lab rats, but also meerkats, ferrets, and even hedgehogs," said Ulyana Krechetova, CT operator, veterinarian, and employee of the Laboratory of Animal Health and Physical Medicine at NSU.

The minipigs were transported to the NSU Laboratory of Experimental Biology and Medicine's tomography center under anesthesia under the supervision of Elena Kuznetsova, Head of the Experimental Biology Clinic at the Institute of Experimental Biology and Medicine. She noted that transporting the minipigs was straightforward due to the close proximity of both institutions. The animals were transferred quickly, so the anesthetic stress on their bodies was minimal.

"We use a modern anesthetic, the same one used in all veterinary clinics, at the same dosages calculated per kilogram of body weight. We calculated the drug's effect for two hours. One hour was spent preparing the animals for the procedures and transporting them. Another hour was required for the CT scan and the return trip. Working with mini-pigs in experiments is comfortable. They tolerate anesthesia well, show no allergic reactions to the medications, and respond well to the contrast agent administered before the CT scan. They also easily enter and exit anesthesia. Today, everything went as planned, without any problems. We are very pleased that NSU now has the only CT scanner licensed for scientific work and animal studies. This opens up great opportunities for our scientists, especially when it's important to obtain scanned images of the organs and systems of the animals involved in the research, before and after the experiments, for comparison," said Elena Kuznetsova.

Collaboration between the two research organizations will continue next year. A series of CT scans on minipigs using the already established system is planned.

— Scientists at the E.N. Meshalkin National Medical Research Center frequently use these objects for research purposes, studying the cardiovascular system and practicing surgical techniques. These areas of activity are of interest to us as well. Therefore, we are interested in implementing joint projects in reconstructive medicine and cardiac surgery using new materials that are being tested specifically on these animal models. Another point of mutual interest for our organizations is that the technique of vascular tomography and the processing of the results obtained during our research have certain specific characteristics and differ from conventional software scans or reconstructions. Using this animal model will help us more deeply and, most importantly, more thoroughly master vascular bed research, which we then plan to apply to other animal species. Collaboration with scientists at the E.N. Meshalkin National Medical Research Center Meshalkin is of great scientific interest to us, as our preclinical work closely intersects with theirs, and we are very pleased to begin this joint research," said Vladimir Kanygin, Head of the NSU Laboratory of Experimental Molecular Biology and Physics.

Histological studies of the cardiac muscle tissue of mini-pigs may also yield interesting results for scientists.

"The myocardium of mini-pigs is anatomically very similar to that of humans, so the transplant material was initially taken from these animal models. Our laboratory will be able to histologically assess myocardial changes following various treatments, including medications. Our institute specializes in myocardial research, and has authored numerous scientific papers on this topic. In this case, my task will be to conduct an initial assessment of such morphological compensatory changes in samples taken following electroanatomical studies," explained Nikolai Kanygin, a junior researcher at the Institute of Molecular Pathology and Pathomorphology (FRC FTM).

That same day, staff from the Novosibirsk State University Faculty of Animal Science and Physical Medicine conducted the first CT scan of a domestic fox. The animal, a 10-year-old, 6 kg female named Zlata, was referred to a laboratory at a Novosibirsk clinic at the request of its owner. This unusual patient tolerated the anesthesia well, and no serious pathologies were detected during the examination. The fox captivated the scientists with her friendliness and beauty. They noted that working with foxes is virtually no different from working with dogs, with the exception of minor details.

Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.

NSU confirmed its position in the group of leading universities of the Priority 2030 program.

Translation. Region: Russian Federation –

Source: Novosibirsk State University –

An important disclaimer is at the bottom of this article.

Council for Support of Development Programs of Universities Participating in the ProgramPriority 2030 summarized the results of its work. Over the course of four days from November 18 to 21, the Ministry of Higher Education and Science, along with experts from the business and scientific communities, reviewed the universities' preliminary results.

NSU has entered the second group of the main track and will receive support in the amount of approximately 400 million rubles for the implementation of the development program in 2026. Yesterday, a press conference was held at TASS with the participation of Andrey Matveyev, Head of the NSU Development Program Coordination Department, and the Deputy Director Institute of Medicine and Medical Technologies of NSU Mikhail Khvostov, Professor of Biomedical Research and Pharmaceutics, presented the key results and research areas that NSU will develop as part of the Priority 2030 program in 2026.

"As part of the development program, which we practically re-formulated at the beginning of this year, we set ourselves the goal of developing NSU as a scientific and technological university. This target model will be implemented through strategic technology projects," Andrey Matveyev noted at the beginning of his speech.

The Center for the Integration of Personalized Biomedicine, Pharmacy, and Synchrotron and Binary Technologies, which was launched this year, became a strategic nuclear technology project (STP) for NSU.

"In a relatively short period of time, we've managed to assemble a fairly large team—over 100 scientists working on interdisciplinary projects. These people possess expertise in various fields, and this helps us implement important, interesting, and breakthrough ideas. We have a very ambitious goal—to develop at least 50 domestic biomedical products by 2030," said Mikhail Khvostov.

Achieving this goal will be facilitated by consolidating the university's activities with research institutes of the Siberian Branch of the Russian Academy of Sciences and industrial partners, as well as NSU's undeniable advantage—fundamental education of the highest level, including in the field of biomedicine.

"Another key development is the construction of a new NSU campus and the development of new infrastructure. This is a research center that will house, among other things, a pilot industrial production facility for biotech products. This infrastructure will accelerate the transfer of new ideas, technologies, and developments generated at NSU and the SB RAS research institutes to the real economy. For biomedical products, this is a long and arduous process; however, the university is now prepared to implement the full life cycle of such products—from conception and prototyping to the transfer of technologies and medical devices to the real economy," added Mikhail Khvostov.

STP's portfolio currently includes over 15 products at various stages of development, representing various segments and primarily related to personalized medicine. All products are being developed with the support of industrial partners, who are ready to bring them to market.

Thus, the development of NGS sequencing platforms potentially enables more accurate diagnosis of various diseases and the prescription of appropriate treatment. Another area of research is related to the SKIF Center for Collective Use, which will enable the full cycle of pre- and post-synchrotron research, which is necessary, for example, for studying potential drugs, their mechanisms of action, and for analyzing pharmaceutical substances.

The most advanced product development is for lower and upper limb prosthetics created using additive manufacturing. Prototypes are currently being tested with patients, and it is planned that this development will be ready for industrial deployment by 2026.

NSU is also currently a site for the development of reagents for the CAR-T therapy ecosystem—one of the modern methods for treating oncohematological diseases.

Another strategic technology project being developed by NSU as part of the Priority 2030 program is "Neural Network Technologies for Processing Targeted Information onboard Small Spacecraft and Controlling Unmanned Aerial Vehicles." It comprises two subprojects. One is related to the development of neural modules that will be installed on satellites. These modules will reduce energy consumption and improve satellite efficiency by pre-processing the information received onboard.

"For example, some of the images received by Earth remote sensing satellites contain cloud cover, which complicates their processing. There's no point in transmitting such images beyond Earth. Neural modules will pre-process the information received by the satellite and transmit only the relevant information to Earth," explained Andrey Matveyev.

The second subproject involves the development of unmanned aerial vehicles with autonomous ground navigation systems, where the drone navigates by analyzing its surroundings and independently performs its assigned task. Such devices have everyday applications, for example, for delivering medicine and essential goods to hard-to-reach areas. Ten such aircraft have already been manufactured for partners.

The third STP—"Artificial Intelligence for Production Facilities and Automation of Industry and the Urban Environment"—includes a range of products and technologies for the efficient management of urban infrastructures and industrial enterprises, automation of production, and improvement of quality of life. Work on the project is being carried out with the support of both large federal and regional companies.

Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.

47 students and 3 NSU faculty members became winners of the Alpha-Future program.

Translation. Region: Russian Federation –

Source: Novosibirsk State University –

An important disclaimer is at the bottom of this article.

On November 20, the auditorium building, part of the new NSU campus, hosted a ceremony to honor scholarship recipients and winners of the faculty grant competition under the "Alpha-Future" platform. This year, 47 NSU students representing all faculties and institutes were among the 3,000 winners from 300 universities across the country. Three faculty members received financial support for their projects—two with Faculty of Natural Sciences and one with Faculty of Economics.

Alpha-Future is a student and university development program across the country. It aims to identify and develop the creative and leadership skills of talented young people, create conditions for their intellectual development, assist them in choosing a career, and increase their motivation to achieve their career goals. Updated in 2025, the program includes two financial support programs: "Alpha-Future Scholarships" for students and "Alpha-Future Grants" for teaching projects.

The first stage of the faculty competition was held within the university: to participate, applicants had to submit documents and a list of personal and academic achievements. One of the mandatory requirements was recommendations from students and the department. During the next stage, information about the selected candidates was sent to the organizers at Alfa-Bank, who conducted the final round and determined the winners.

The following were the recipients of grants from NSU:

Anna Vladimirovna Komarova, Associate Professor of the Department of Political Economy at the Faculty of Economics at NSU. Sergey Evgenievich Sedykh, Senior Lecturer at the Faculty of Natural Sciences, PhD in Biology, and Research Fellow at the Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the Russian Academy of Sciences. Daria Sergeevna Novopashina, Associate Professor of the Department of Molecular Biology and Biotechnology at the Faculty of Natural Sciences.

The grant is 250,000 rubles, and funds can be used for professional development and educational purposes. Teachers will also have the opportunity to participate in relevant events and projects within the Alpha-Future platform.

"I have a lot of experience applying for grants, but this was my first time applying for a grant from Alfa-Bank. The application required me to highlight all my accomplishments and demonstrate that we truly want to use the grant funds for good, worthy causes. I'm very glad that such awards for teachers exist and that they're being developed. Large companies are now starting to establish closer ties with students and their teachers. This is very valuable for us because we better understand the current labor market trends. And this kind of direct financial support is certainly a great incentive and fosters loyalty to the company," commented Anna Komarova.

Sergey Sedykh, on the other hand, had never participated in such competitions for teachers, but this time he decided to give it a try.

"During my preparation, I was surprised by how many personal achievements and scientific papers I had accumulated. I received recommendations from 12 students, not only from NSU but also from other universities. I plan to use half of the grant to pay for the authors of assignments for the "Genome Editing" track of the National Technology Olympiad, which I organize, and the other half for conference travel. I am very grateful to my students for their trust, and to the university for supporting my candidacy.

Daria Novopashina plans to invest in self-development and exploring new areas.

"I wanted to improve my design skills. I want to create engaging presentations, pictures, and sketches to engage students in the learning process. I also plan to develop a new teaching aid, which requires knowledge of how to write texts effectively."

Among the NSU scholarship recipients, the Faculty of Natural Sciences has the largest number of students (14), followed by the Faculty of Economics (10), and the Faculty of Physics (7). The Humanities Institute and the Institute of Philosophy and Law have received five and four scholarship recipients, respectively. The Faculty of Information Technology and the Institute of Medicine and Medical Technologies have received two scholarship recipients each, while the Faculty of Mechanics and Mathematics, the Faculty of Geology and Geophysics, and the Institute of Intelligent Robotics have received one scholarship each. All recipients will receive monthly stipends of 5,000 rubles from September 2025 to June 2026.

Full list of scholarship recipients:

1. Egorov Dmitry Alexandrovich, FF

2. Vopilovsky Alexey Mikhailovich, FF

3. Vanda Vladislav Sergeevich, FF

4. Borozdin Pavel Aleksandrovich, FF

5. Olga Vladimirovna Somova, Faculty of Economics

6. Morozova Yesenia Shamilevna, GI

7. Voronin Andrey Alekseevich, FEN

8. Shepelev Vitaly Denisovich, MMF

9. Shuklina Anna Artyomovna, FF

10. Frolova Anna Alekseevna, IFP

11. Martyushova Vladislava Gennadievna, FEN

12. Evgeniya Dmitrievna Pozdnyakova, FEN

13. Rudnev Daniil Nikolaevich, FF

14. Muravyov Mikhail Denisovich, EF

15. Denisova Anna Maksimovna, EF

16. Kozlenko Mikhail Mikhailovich, GGF

17. Buzin Mikhail Andreevich, IFP

18. Gerasimov Vladislav Sergeevich, IFP

19. Chumak Anton Maksimovich, FIT

20. Bronnikova Ksenia Evgenievna, IFP

21. Feoktistov Grigory Olegovich, GI

22. Kurbatsky Dmitry Vladimirovich, FEN

23. Nechaeva Maria Stanislavovna, GI

24. Ivanov Alexey Mikhailovich, FEN

25. Skotareva Anna Evgenievna, FEN

26. Frolov Ivan Andreevich, FEN

27. Kulyaeva Anastasia Evgenievna, GI

28. Motina Alina Nikolaevna, GI

29. Bikeev Nail Rafikovich, FEN

30. Novikov Maxim Aleksandrovich, FEN

31. Pronina Maria Evgenievna, IMMT

32. Chernovsky Nikita Dmitrievich, FEN

33. Petrochenko Sofia Aleksandrovna, FEN

34. Pereverzev Ilya Maksimovich, FIT

35. Aksenova Olesya Dmitrievna, FEN

36. Borodin Kirill Andreevich, IIR

37. Churkina Alina Ilgizovna, Faculty of Economics

38. Lysova Sofia Antonovna, EF

39. Guseva Veronika Andreevna, EF

40. Denishkina Anastasia Alexandrovna, EF

41. Isaev Alexey Sergeevich, IMMT

42. Makogon Ulyana Arkadyevna, FEN

43. Starukhin Ivan Nikolaevich, FF

44. Yakovleva Elizaveta Aleksandrovna, EF

45. Nafikov Marat Damirovich, FEN

46. Varfolomeeva Victoria Aleksandrovna, EF

47. Vaskin Mikhail Vladimirovich, EF

Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.

588 NSU students applied to participate in the "I am a Professional" Olympiad.

Translation. Region: Russian Federation –

Source: Novosibirsk State University –

An important disclaimer is at the bottom of this article.

The results of the registration campaign have been summed up IX season of the All-Russian student Olympiad "I am a professional" The presidential platform "Russia – Land of Opportunity" received over 215,000 applications, including 3,290 students from Novosibirsk Oblast universities. The region ranked among the top 20 in terms of number of Olympiad participants. The project is supported by the Russian Ministry of Science and Higher Education.

A total of 215,515 participants, representing 1,099 Russian universities and their branches, applied this season. The organizers prepared even more opportunities for students to grow professionally and launch their careers: 70 disciplines were available, including areas that are a priority for ensuring the country's technological sovereignty. The "I am a Professional" Olympiad annually brings together the most talented and active students and promotes professionalism as a value.

"Talented young people from the Novosibirsk Region are forming Russia's talent pool, demonstrating their high professionalism in projects of the "Russia – Land of Opportunity" Presidential Platform, including the "I Am a Professional" Olympiad. Students from 21 regional universities and branches applied to participate in the ninth season of the project. The most active participants were from the Siberian State Transport University (663 participants), Novosibirsk National Research State University (588), and the Siberian Institute of Management (branch) of the Russian Presidential Academy of National Economy and Public Administration (516). I thank everyone who participates in the Presidential Platform competitions: learn, develop, and we will always help you along the way," said Andrey Betin, CEO of the "Russia – Land of Opportunity" Presidential Platform and Rector of the Senezh Management Workshop.

According to Valeria Kasamara, director of the All-Russian Student Olympiad "I am a Professional," the Novosibirsk Region demonstrates high activity in the project every year.

"The 'I Am a Professional' Olympiad fosters a professional self-determination environment for young people, and this is particularly noticeable at the regional level. In the Novosibirsk Region, we've seen growing interest in the project: 3,290 students have chosen the Olympiad as a way to launch their careers, choosing fields such as Mathematics, Transportation, and Psychology," noted Valeria Kasamara.

A key feature of the new season will be a stronger career component. From the early stages, participants will have access to a comprehensive database of internships and job openings from over 700 industry partners. They will have the opportunity to attend career counseling sessions, attend specialized schools, and receive job offers.

The qualifying round for the ninth season of the All-Russian Student Olympiad "I Am a Professional" (I Am a Professional), part of the Presidential Platform "Russia – Land of Opportunities," is scheduled for November 14 to December 1. It will allow participants to not only test their knowledge but also solve practical problems from leading universities and employers. Olympiad winners will receive significant benefits, including preferential admission to master's and doctoral programs, as well as cash bonuses of up to 300,000 rubles for medalists.

Let us remember that in the previous Olympic season NSU students represented 827 in the selection round, and 197 in the finals. The top five most popular tracks among NSU students were Biology, Biotechnology, Bioengineering and Bioinformatics, Chemistry, and Mathematics. NSU students performed best in Biotechnology, Bioengineering and Bioinformatics, Biology, and Ecology. NSU students received 75 diplomas and six medalists in the Olympiad.

The All-Russian Student Olympiad "I am a Professional" is being implemented as part of the federal project "Russia – Land of Opportunity" of the national project "Youth and Children" with the support of the Ministry of Science and Higher Education of Russia.

This news was prepared based on materials from the press service of the "I am a Professional" Olympiad.

Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.

Three NSU students have become recipients of the "Investing in the Future" scholarship program.

Translation. Region: Russian Federation –

Source: Novosibirsk State University –

An important disclaimer is at the bottom of this article.

Three students from the Faculty of Economics at Novosibirsk State University have won the "Investments in the Future" scholarship program for financial market organizations, established by BrokerCreditService LLC (BCS).

Based on the results of the Scholarship Council vote, scholarships were awarded to:

Semyon Afanasyev, a second-year Master's student in Management (major: Innovative Entrepreneurship and Management); Anastasia Batueva, a fourth-year student in Economics (major: Modern Economic Modeling: Traditional Approaches, Behavioral Economics, and Econometric Analysis); and Matvey Khoroshilov, a second-year Master's student in Economics (same major).

Each scholarship recipient will receive 10,000 rubles monthly for a year—from September 2025 to August 2026. The total scholarship amount is 120,000 rubles.

The scholarship program is aimed at supporting talented students with an interest in economics, investments, and the financial market. Participants undergo a competitive selection process: they submit a portfolio of achievements, a reference, a motivation letter, and a video business card.

"To participate, I had to gather a large package of documents—a reference, a motivation letter, and a video business card. I participated last year and also won a scholarship, so I decided to try again. I'm thrilled to have won. It's great that there are proactive people and organizations willing to support students," said Anastasia Batueva.

"I decided to participate because my research and practical interests are closely related to the financial market. The program is conducted remotely: you need to gather documents, record a video, and prepare a motivation letter. Upon learning of my victory, I felt immense gratitude to the founder, BCS," noted Matvey Khoroshilov.

The "Investing in the Future" scholarship program is implemented by Russian financial market organizations to support and develop students pursuing careers in finance, investment, and economic analysis.

Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.

A NSU graduate student has developed a method for producing a solid form of the active ingredient of an anti-smallpox drug.

Translation. Region: Russian Federation –

Source: Novosibirsk State University –

An important disclaimer is at the bottom of this article.

A first-year master's student at the Department of Solid State Chemistry (SSC) is conducting a study on the stability of the antiviral compound tecovirimat. Faculty of Natural Sciences (FNS) of Novosibirsk State University Alexander Ivlev, under the scientific supervision of Sergey Arkhipov, a senior lecturer in the Solid State Chemistry Department at the NSU Natural Sciences Department and a candidate of chemical sciences, and Dmitry Kolybalov, an assistant at the Solid State Chemistry Department at the NSU Natural Sciences Department. As part of their work, the scientists addressed the problem of the lack of reproducibility in experiments to obtain solid forms of the active ingredient in an anti-smallpox drug. They proposed new methods for producing several solid forms, one of which is currently undergoing patenting.

— It is generally accepted that humanity has conquered the smallpox virus (VARV). The eradication of the deadly disease it causes was confirmed in 1980 at a meeting of the World Health Assembly. There, a decision was made to halt mass vaccination against this virus, which ultimately led to a significant decline in the population's immunity to all orthopoxviruses—a large family of DNA viruses that include the causative agents of diseases such as smallpox, cowpox, and monkeypox (MPXV). Smallpox is transmitted only from person to person, but other orthopoxviruses can be transmitted from animals to humans. One such virus is monkeypox. In 2022, the World Health Organization (WHO) declared the monkeypox outbreak a public health emergency of international concern. According to the WHO, from January 1, 2022, to April 30, 2025, a total of 142,141 laboratory-transmitted cases of MPXV infection were recorded, 328 of which were fatal. Work is currently underway to develop and improve vaccines, diagnostic tests, and drugs to combat the monkeypox virus. And with our research, we are contributing to solving this global problem, said Alexander Ivlev.

Tecovirimat is a chemical compound with antiviral activity against orthopoxviruses. In January 2022, the European Medicines Agency approved TPOXX®, whose active ingredient is tecovirimat, for the treatment of monkeypox virus disease. In 2023, NIOH-14, a prodrug of tecovirimat, was introduced into the Russian Federation. Tecovirimat exhibits exceptional activity against smallpox, monkeypox, cowpox, vaccinia, and other orthopoxviruses while exhibiting low toxicity. It acts by targeting the viral protein p37, which prevents the release of the virus from the infected cell and ultimately prevents its spread throughout the body. Two dosage forms of tecovirimat are currently available: capsules for oral administration and powder for intravenous injection.

Each dosage form has its own limitations and storage temperature requirements. Capsules must be stored at a temperature of 20°C to 25°C, but a temperature range of 15°C to 30°C is acceptable. Injectable powder must be stored at a temperature of 2°C to 8°C; short-term storage (up to 24 hours) at ambient temperature is permitted; freezing is not permitted. The development of this dosage form has expanded the scope of tecovirimat's use.

This drug is patented by the American company SIGA technologies. The crystal structure of tecovirimat monohydrate (solid form III) has been determined and deposited in the Cambridge Crystallographic Data Center. To date, SIGA technologies has discovered six structurally distinct solid forms of tecovirimat: two monohydrates, one hemihydrate, and three anhydrous forms. However, the crystal structure has only been determined for tecovirimat monohydrate, which is solid form III, which is easily prepared but is metastable at room temperature and gradually converts to solid form I. The crystal structures of the remaining solid forms remain unknown.

"We are studying the stability of solid forms of tecovirimat under changing environmental conditions. During the previous phase of the study, supported by the Priority 2030 program, we identified conditions for the reproducible production of solid forms of tecovirimat, determined the crystal structures of five of the six known solid forms, and identified differences in their structures. Different solid forms containing the same compound can differ significantly in their physicochemical properties (in particular, apparent solubility and dissolution rate), so this information is crucial for identifying existing solid forms and searching for new solid forms of tecovirimat, as well as developing methods for their production. Equally important is data on the stability and interconversion of different solid forms of tecovirimat, as this directly impacts the storage conditions of the dosage forms," explained Alexander Ivlev.

In a new phase of their research, the scientists addressed the critical issue of the lack of reproducibility in experiments producing solid forms of tecovirimat. They identified previously undescribed methods for producing these forms, one of which is currently undergoing patenting. A reproducible method for producing a desired solid form allows the scientists to synthesize the required quantity of the desired form, fully characterize the properties of the resulting compound, grow crystals, and determine its spatial structure and properties. The method chosen for patenting has significant potential for scalability.

Currently, the scientists have produced sufficient quantities of each solid form of tecovirimat for study, and for each, they have obtained powder diffraction profiles of higher quality than those presented in the SIGA technologies patent. For three solid forms of tecovirimat, the scientists have already demonstrated stability at low temperatures. Such data for the solid forms under study have not previously been described in the literature. Experiments are currently underway to study the stability of solid forms of tecovirimat in high-humidity environments. Combined with experiments on the effects of temperature, this will allow conclusions to be drawn regarding the feasibility of their use in the development of new dosage forms of the smallpox drug based on a metastable solid form.

To study the structures and properties of various forms of tecovirimat, the young scientist employed several methods: X-ray diffraction analysis, X-ray structural analysis, and differential scanning calorimetry. Using powder X-ray diffraction (XRD), diffraction patterns unique to each solid form were obtained and the phase purity of the crystalline product was assessed. The crystal structure of the studied substances was deciphered using single-crystal X-ray diffraction (XRD). The response of the studied forms of tecovirimat to temperature changes was determined using differential scanning calorimetry (DSC). Based on the nature of the effects upon heating or cooling the sample, they determined which solid form was more stable and determined the temperature at which one form could transform into the other, altering its crystalline structure.

Currently, the young researcher is working to determine the structure of the final, sixth, solid form of tecovirimate. The method for its production has already been discovered; the conditions for producing crystals remain to be determined. Next, they plan to search for new solid forms of tecovirimate and study their physicochemical properties. The next stage of the project will involve mechanochemical studies.

"In production, mechanical action is used to grind particles of pharmaceutical substances, but this can also lead to the transition of one solid form to another. That is, a solid form of a substance can change its crystalline structure and transform into another solid form of the same compound. And since powders of future drug substances can be subject to mechanical action in industrial settings, it is crucial to know in advance what consequences this technical process may cause," explained Alexander Ivlev.

The final stage of the work involves cocrystallizing the active ingredient of TPOXX® with other compounds to produce solid forms in which the tecovirimat molecule will be bound to other molecules via intermolecular interactions. Such experiments are necessary to obtain new solid forms with improved properties, which should ultimately improve the properties of the final product, such as its solubility or temperature stability.

"I hope that our work will ultimately lead to improved efficacy of the drug and help doctors in their work," said Alexander Ivlev.

This work is being carried out with the support of the Priority 2030 program within the framework of the youth research project competition “X-ray, synchrotron, and neutron methods of interdisciplinary research.”

Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.

NSU teams won prizes at the third all-Russian competition for formal program verification, VeHa-2025.

Translation. Region: Russian Federation –

Source: Novosibirsk State University –

An important disclaimer is at the bottom of this article.

The third All-Russian competition in formal program verification, VeHa-2025, took place from November 4–8 as a satellite event of the 26th Open All-Siberian Programming Olympiad named after I.V. Pottosin. Representatives from leading Russian companies, universities, and research institutes participated in the competition.

The competition's problems focused on verifying the correctness of software systems—from algorithms for solving Diophantine equations using the Indian "chakravala" method and searching for substrings in a text string to control models for Chinese high-speed trains and static program analysis. Participants had to delve into their chosen domain and prove the correctness of their algorithms using formal verification methods.

VeHa-2025 featured teams from Novosibirsk State University, Astra Group, Kaspersky Lab, the Ivannikov Institute for System Programming of the Russian Academy of Sciences, the Steklov Mathematical Institute of the Russian Academy of Sciences, Peter the Great St. Petersburg Polytechnic University, Bauman Moscow State Technical University, Neapolis Paphos University, Moscow Institute of Physics and Technology, ITMO University, MISIS University, and the Institute of Automation and Electrometry of the Siberian Branch of the Russian Academy of Sciences.

The NSU teams demonstrated strong results. In the "Step-by-Step Property Inference in Isabelle/HOL" category (Kaspersky Lab), second place was shared by:

— Artem Ishchenko, a postgraduate student at the Faculty of Information Technology (FIT); Lev Boyandin, a third-year student at the Faculty of Mechanics and Mathematics (MMF).

First place was taken by FIT graduate and now PhD student at the Institute of Architecture and Economics, Ivan Chernenko.

"I'm interested in formal methods and interactive theorem proving systems, so the competition topic was very relatable to me. I participated remotely and discussed the issues with my mentor in a group discussion. Due to my workload, I only chose one category—Isabelle/HOL. There were a couple of challenging moments, but overall, everything went smoothly. I was pleased with the level of difficulty. I'm very happy to have won a prize," said Lev Boyandin.

The team led by fourth-year FIT student Margarita Shabanova was particularly noteworthy, becoming the only nominee for a problem that closely approximated a real-world industrial setting, modeling the control system of Chinese high-speed trains. Also competing were Faculty of Mathematics and Mechanics (FMM) student Alexander Kharkov and Faculty of Mathematics and Mechanics Master's student Yulia Razbitnova.

"The Olympiad's theme coincided with the focus of my thesis, and I wanted to gain useful skills and broaden my horizons. It was interesting to test my skills on problems beyond the curriculum. The competition was very dynamic: we had to quickly understand the problem and come up with a solution within a limited time. The atmosphere was professional yet friendly—the organizers responded promptly to questions," Margarita Shabanova shared her impressions.

We congratulate the participants and wish them continued success in their research and project work!

Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.

The NSU team presented the results of its work within the framework of the Priority 2030 program.

Translation. Region: Russian Federation –

Source: Novosibirsk State University –

An important disclaimer is at the bottom of this article.

Today, the Novosibirsk State University team presented to the Council for Support of Development Programs the results of its work for 2025 on strategic technology projects implemented within the framework of the program of the Ministry of Science and Higher Education of Russia.Priority 2030.

NSU was represented at the council meeting by Rector Mikhail Fedoruk, Director of the Institute of Medicine and Medical Technologies Yulia Samoilova, Head of the Academic Policy Department Marina Shashkova, a representative of the industrial partner, Director of the Medical and Biological Union LLC Mikhail Losev, and Governor of the Novosibirsk Region Andrei Travnikov.

Andrey Travnikov noted the importance of university interactions with industry and the growing role of universities in the region's economy:

NSU graduates are the main residents and users of AkademPark's infrastructure, which within its perimeter alone generates 30 billion rubles in revenue today, and if you include companies associated with AkademPark, the figure approaches 60 billion. This is a significant contribution to our economy.

The governor also drew attention to the relevance of biotechnology, which is represented in the university's project portfolio:

"This is important for the Novosibirsk Region because the industry is actively developing, responding to the challenges of the pandemic and import substitution. Scientific support and training of new personnel for this industry are essential."

In his speech, NSU Rector Mikhail Fedoruk emphasized the changing role of the university in the ecosystem of the Novosibirsk Scientific Center.

"Novosibirsk State University was created as an integral part of Akademgorodok, where the Academy of Sciences served as the integration center and driving force. In recent years, the situation has changed: now, the university is taking on the role of a development driver and a hub for the integration of science, industry, and education. Our strategic technology projects are prototypes for integration centers in areas new to Akademgorodok, where the university aspires to become a leader," noted Mikhail Fedoruk.

The university's development strategy through 2036 envisions a transition to a scientific and technological university model, where, alongside education and research, the creation of products and technologies becomes a third core activity. Strategic technology projects are an important component of this transition, in which industrial partners act not only as development commissioners but also are involved in personnel training and management processes. At the same time, the university remains true to its principles: strong fundamental training, the involvement of practitioners from research institutes and industry in teaching, and the involvement of students in research and development from their junior years.

The NSU development program includes three strategic technology projects (STP): "Center for the Integration of Personalized Biomedicine, Pharmacy, and Synchrotron and Binary Technologies," "Neural Network Technologies for Processing Targeted Information onboard Small Spacecraft and Control of Unmanned Aerial Vehicles," and "Artificial Intelligence for Production Facilities and the Automation of Industry and the Urban Environment."

At the Priority 2030 Program Council meeting, NSU presented the first project in more detail. Biomedicine is a new area for NSU, the launch of which was made possible by the consolidation of scientific and technological research resources from the SB RAS and NSU institutes, the availability of infrastructure to accelerate technology transfer (the construction of a new NSU campus), and the strong fundamental training of personnel at the university.

"The goal of the STP is to develop the full life cycle of a biomedical product, from the initial idea to the prototype's deployment in the real economy. The project brings together over 100 specialists from various scientific fields and leading universities in the industry. The project's implementation entails a profound transformation of many processes at the university, including a change in the educational model, where students are involved in all stages of the process, from the initial idea to the prototype's development," added Mykhailo Fedoruk.

Key achievements in 2025 as part of the biomedicine project include the development of software for processing and analyzing genomic data (a web platform for automated processing of genetic testing results); the creation of a reagent for detecting CD19-specific CAR T and CAR NK cells suitable for quality control of personalized therapy products; the development of a system for assessing the biomechanical gait parameters of lower-limb amputees; the creation of a final prototype of a prosthetic socket for a forearm prosthesis manufactured using 3D printing, as well as a prototype of a printed prosthetic socket for a leg prosthesis for transtibial amputations.

Construction is currently underway on a new research center and educational and scientific center for the Institute of Medicine and Medical Technologies of NSU with an area of over 23 thousand square meters; they are related to the facilitiesnew campus of NSU, being built as part of the national project "Youth and Children." This infrastructure will be used to develop biomedical research. The unifying principle of all product lines of this strategic technology project is the creation of integrated technological platforms that can be adapted to various clinical needs. All developments and research are being conducted with the active participation of industrial partners, including the Medical and Biological Union, the Siberian Ring Photon Source (SKIF) Shared Use Center, Generium JSC, the Moscow Prosthetic and Orthopedic Enterprise, ORTOS, and Rostec.

"This project combines our country's most ambitious goals: national health, independence from imports, and a high level of education for future generations. As part of the project, we are creating a modular platform for targeted NGS sequencing based on probe enrichment hybridization technology—the first used in domestic diagnostic reagents. The system being developed will allow for flexible scaling of panels—from highly specialized ones, including several genes, to whole-exome solutions covering a wide range of diseases, from cancer to rare hereditary pathologies. Domestic enrichment hybridization technology can become the basis for highly accurate next-generation diagnostic solutions, fully compatible with the Russian infrastructure and the needs of clinical genomics," commented project manager Yulia Samoylova.

"The development of domestic reagents for NGS sequencing is a key element in personalized medicine. Accurate information about a tumor's mutational profile allows doctors to make the right decision: prescribing targeted therapy when it's truly effective or avoiding unnecessary prescriptions of expensive drugs. This not only improves the quality of treatment but also optimizes healthcare costs. By supporting this project, we are providing Russian oncologists with a modern tool for informed clinical decisions," added Mikhail Losev, CEO of the Medical and Biological Union.

Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.

NSU has developed software for the comprehensive processing and analysis of genomic data.

Translation. Region: Russian Federation –

Source: Novosibirsk State University –

An important disclaimer is at the bottom of this article.

VarAn (variant, analyzer) software, designed for the comprehensive processing and analysis of genomic data obtained by high-throughput sequencing, was developed by researchers at the Bioinformatics Laboratory. Institute of Medicine and Medical Technologies (IMMT) of Novosibirsk State UniversityIn September of this year, the program received a state registration certificate, legally securing the copyright to the development and opening the door to its further commercialization and implementation in clinical practice. In the near future, the developers will submit to the Federal Service for Surveillance in Healthcare (Roszdravnadzor) a complete package of documents required to obtain a registration certificate for the medical device, which this application will serve as. The next stage of the project involves clinical trials of the developed solutions, using clinical samples and evaluating the system's diagnostic performance under real-world conditions.

— In recent years, with the active introduction of genetic testing in the diagnosis of hereditary and oncological diseases, the need for specialized software capable of coping with these tasks has increased significantly. Programs similar in functionality to our development exist in Russia and abroad, but the difference between our product is its ability to support a wider range of possible analyzes and evaluate both somatic and hereditary mutations, which expands the possibilities of its use and provides advantages for use in clinical practice. Our program analyzes DNA sequencing data. This process is the reading of a DNA sequence. This is important because many diseases – both hereditary and oncological – arise precisely because of the replacement of the DNA sequence. To prescribe specialized treatment, it is necessary to read the patient’s DNA sequence and determine which mutation caused the disease. Until recently, specialists could only read very short fragments of it, and not with the highest accuracy. And to obtain reliable information about an existing mutation, it is necessary to read many such sequences. The result is millions of short reads, and in order to identify the desired mutations in this array of information, it is necessary to perform complex computer processing of the available data. Our VarAn software performs all the stages of analyzing such short DNA reads: assessing their quality, filtering, and then mapping to the reference genome, determining the mutation and its annotation – does it affect the protein, is it responsible for the presence of any disease. As a result, the user receives a full report that lists all potentially significant clinical mutations,” explained VarAn software developer, junior researcher at the Bioinformatics Laboratory of the Institute of Medical Sciences of NSU Alexander Vikhorev.

VarAn software has a wide range of applications. It is designed for automated analysis of high-throughput sequencing (NGS) data in clinical practice to identify and interpret pathogenic genetic variants for diagnostic purposes. The program covers the full data processing cycle: from raw sequencing data quality control (FASTQ) to generating a clinical report containing annotated variants with established diagnostic significance.

"Our VarAn app is a standalone product with expanded functionality for clinical diagnostics. It offers versatility for a wide range of genetic studies and provides comprehensive bioinformatics analysis with automated interpretation of the clinical significance of identified variants. It integrates the full NGS data processing cycle into a single software environment. The output data is intended for use by medical professionals in making diagnostic decisions and developing personalized therapeutic strategies," explained Alexander Vikhorev.

The VarAn app features a user-friendly, intuitive interface for managing analysis results and provides a secure connection to ensure the confidentiality of medical data. Using it requires no specialized knowledge, let alone programming skills. The results display form is also extremely user-friendly.

"Our software is designed for a select group of professional users, primarily scientists and geneticists. For their convenience, the application has preset optimal parameters: simply upload sample data, initiate the analysis using a simple web form, select a few parameters—for example, the genome version—and run the process. Then, simply wait for the analysis to complete, which, depending on the data volume, can take anywhere from a few hours to several days. The results viewer is also extremely simple and user-friendly. Right on the application's website, you can view mutations, filter them, view the results in a genomic browser, and receive a detailed sequencing quality report. If necessary, you can download the results as an Excel spreadsheet for further independent work with them offline. Any physician can initiate the analysis using our website; no specialized programming knowledge or specialized applications are required," the developer explained.

The web application is hosted on the varan.nsu.ru domain, where technical testing of the system is currently underway using real genomic data. Laboratory staff are conducting these tests internally, without the involvement of external users. The reference genomes used in the tests have previously been sequenced and analyzed multiple times by specialists, who identified reference mutations in them. The website has successfully passed all operational modes, demonstrating the software's high sensitivity and specificity.

VarAn software was created as part of a project to develop comprehensive disease diagnostic solutions using whole-genome sequencing and microfluidic technologies. This project is part of the strategic technology project "Center for the Integration of Biomedicine and Pharmaceutics," implemented with the support of the Priority 2030 program.

Material prepared by: Elena Panfilo, NSU press service

Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.

NSU scientists took part in the creation of an international database on chronic heart failure

Translation. Region: Russian Federation –

Source: Novosibirsk State University –

An important disclaimer is at the bottom of this article.

Employees Institute of Medicine and Medical Technologies of Novosibirsk State University (IMMT NSU) Participants in an international Russian-Kazakh study analyzing patients with chronic heart failure (CHF) who were or were not prescribed cardiac resynchronization therapy (CRT). The Russian portion of the project was led by Anton Yurkovsky, a resident at the Institute of Medical and Mechanics of the Novosibirsk State University.

Current guidelines emphasize the importance of a comprehensive approach—integrating drug and device therapy to maximize the lifespan of patients with CHF. Professor and MD Natalia Lozhkina, one of the study participants, comments on the practical impact of these strategies:

"Over the past decades, a number of medications have been developed (ACE inhibitors or sartans, beta-blockers, diuretics, and modern combination therapies), which, taken together, have increased the life expectancy of patients with CHF by approximately six to eight years. However, this is where pharmacological options are limited. The next step in treatment is cardiac resynchronization therapy (CRT)—the implantation of a special device that synchronizes the ventricles. This increases the efficiency of cardiac contractions and improves patient well-being," explained Natalia Lozhkina.

In Russia, cardiac resynchronization therapy remains inaccessible to most patients, while in Kazakhstan there are more opportunities for its use.

Scientists from NSU, together with colleagues from a medical center in Almaty, compared clinical, demographic, instrumental, biochemical, and drug treatment data in patients with CHF with reduced left ventricular ejection fraction in several hundred patients, both those who underwent CRT and those who did not, over a five-year follow-up period. Based on this data, the study authors developed a unique approach for assessing the five-year prognosis in patients with severe, end-stage CHF.

"By comparing data from Russian and Kazakh patients, we convincingly demonstrated that cardiac resynchronization therapy with defibrillator function, especially in patients with an extremely low left ventricular ejection fraction, can extend their lives by an additional five years or more. This period may be sufficient to wait until their turn for a donor heart transplant. Simply put, this treatment significantly improves the survival rate of such patients, of whom, I repeat, there are quite a few," noted Natalia Lozhkina.

The study results will soon be published in a number of high-impact scientific journals and presented at a meeting of the regional branch of the Russian Society of Cardiology. According to the scientists, this will significantly increase the chances of including cardiac resynchronization therapy in the list of services available under the compulsory medical insurance system in our country. The researchers also plan to use the database they created for other research projects related to assessing the effectiveness of various approaches to treating CHF.

Chronic heart failure (CHF) is a clinical syndrome characterized by typical symptoms (shortness of breath, fatigue, edema) caused by structural and/or functional abnormalities of the heart, which lead to ineffective blood supply to the body at rest or under stress. According to the European Society of Cardiology, CHF is associated with a significant reduction in quality of life, a high risk of rehospitalization, and early mortality: without treatment of the underlying disorder, approximately 50% of patients die within four years of diagnosis, and in severe cases, more than half die within the first year. Along with its high mortality rate, CHF remains a leading cause of disability, significantly reducing life expectancy and leading to significant loss of active working years due to progressive deterioration of physical and social adaptation.

Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.